紫杉醇+顺铂方案联合沙利度胺治疗晚期非小细胞肺癌的临床研究

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (3): 317-321.

紫杉醇+顺铂方案联合沙利度胺治疗晚期非小细胞肺癌的临床研究

彭晔¹, 王美芹², 谢娜¹, 李燕¹, 卢海燕¹, 李炳茂²

¹河北省衡水市哈励逊国际和平医院肿瘤内科
²中医科,衡水 053000,河北

收稿日期:2012-12-12 修回日期:2013-03-04 出版日期:2013-03-26 发布日期:2013-04-02
作者简介:彭晔,女,硕士,研究方向: 恶性肿瘤化疗。Tel: 18003188821 E-mail: pengye666@sina.com

Randomized study of thalidomide in combination with TP chemotherapy for the treatment of advanced non-small-cell lung cancer

PENG Ye¹, WANG Mei-qin², XIE Na¹, LI Yan¹, LU Hai-yan¹, LI Bing-mao²

¹Department of Oncology
²Traditional Chinese Medicine, Harrison International Peace Hospital, Hengshui 053000,Hebei, China

Received:2012-12-12 Revised:2013-03-04 Online:2013-03-26 Published:2013-04-02

摘要/Abstract

摘要： 目的: 观察紫杉醇+顺铂(TP)方案联合沙利度胺治疗晚期非小细胞肺癌患者的疗效和安全性。方法: 选择晚期非小细胞肺癌(NSCLC)患者110例,均为ⅢB-Ⅳ期患者,随机分为两组:治疗组55例,给予TP方案联合沙利度胺治疗,21 d 为一周期,并于化疗第一天起给予沙利度胺 100 mg/d, 睡前顿服, 若能耐受,一周后加至 200 mg/d,连续口服3个月;对照组55例,单纯TP方案化疗。所有病例均为初治患者,以前未进行过放化疗,入组的每例患者至少接受2个周期的治疗。结果: 治疗组与对照组有效率分别为 41.18%、37.74%,两组间差异无统计学意义(P＞0.05);临床获益率分别为 86.27%、69.81%,治疗组明显高于对照组(P＜0.05);治疗组食欲增加率、体重增加率及KPS评分好转率均优于对照组(P<0.05)。中位无进展生存时间(PFS)治疗组为 7.45 个月(5～26个月),对照组5.77个月(4～20个月);中位总生存期(OS)治疗组为 12.88 个月(6～26个月),对照组为11.32个月(5～21个月)(P＜0.05)。两组Ⅲ-Ⅳ级不良反应均较少见,除Ⅲ-Ⅳ级恶心、呕吐发生率治疗组明显低于对照组外(P=0.03),余不良反应发生率两组无明显差异(P＞0.05)。沙利度胺最常见的不良反应嗜睡、便秘发生率低(10%～30%),不良反应较轻。结论: TP方案联合沙利度胺治疗晚期NSCLC未能明显提高近期疗效,但临床获益率、生活质量明显提高,生存期延长,无明显毒副作用,安全性高,值得临床推广应用。

关键词: 紫杉醇+顺铂方案, 沙利度胺, 晚期非小细胞肺癌, 化疗

Abstract: AIM: To evaluate the efficacy and safety in the patients with advanced non-small cell lung cancer (NSCLC), treated with thalidomide combined with paclitaxel plus cis-platinum (TP) chemotherapy.METHODS: 110 patients with stages ⅢB and Ⅳ NSCLC were divided randomly into two groups, the trial and the control groups. The trial group were treated with thalidomide and TP chemotherapy, in which thalidomide was given 100 mg per night for the first week and then added to 200 mg per night for 3 months if tolerable. The control group were treated with TP chemotherapy only. All patients were treated primarily and received treatments for at least two periods, 21 days for one period.RESULTS: Of 110 assessable patients, the overall response rate was 41.18% in the trial group and 37.74% in the control group (P＞0.05). The clinical benefit rate was 86.27% in the trial group and 69.81% in the control group (P＜0.05). Besides, the trial group indicated considerable improvement as compared with the control group in the increased appetite rate, weight gain rate and the KPS score improvement rate. The median PFS was 7.45 (5-26) months for the trial group, and 5.77 (4-20) months for the control group (P<0.05); The median OS was 12.88 (6-26) months for the trial group, and 11.32 (5-21) months for the control group (P<0.05).The Ⅲ -Ⅳ grade untoward effects were rare in both groups.Nausea,vomiting of Ⅲ-Ⅳ grade incidence in the treatment group was significantly lower than the control group (P=0.03). But there were no significant differences in the remaining toxicities between the two groups (P＞0.05). The most common untoward effects of thalidomide, somnolence and constipation, were rare (incidence rate 10%-30%).CONCLUSION: Though without considerable improvement in short term efficacy, TP regimen combined with thalidomide with high safety significantly improve clinical benefit rate, quality of life and free survival in patients with advanced NSCLC. Therefore the treatment of TP regimen combined with thalidomide deserves clinical popularization.

Key words: TP regimen, Thalidomide, Advanced non-small cell lung cancer, Chemotherapy

中图分类号:

R734

彭晔, 王美芹, 谢娜, 李燕, 卢海燕, 李炳茂. 紫杉醇+顺铂方案联合沙利度胺治疗晚期非小细胞肺癌的临床研究[J]. 中国临床药理学与治疗学, 2013, 18(3): 317-321.

PENG Ye, WANG Mei-qin, XIE Na, LI Yan, LU Hai-yan, LI Bing-mao. Randomized study of thalidomide in combination with TP chemotherapy for the treatment of advanced non-small-cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(3): 317-321.

[1]	王如玥, 谢飞, 王欣, 李红玉. 脾多肽注射液对化疗后KM小鼠骨髓抑制和免疫力低下的治疗作用[J]. 中国临床药理学与治疗学, 2023, 28(9): 1000-1007.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	李爽, 韩淑贞, 戴瑜婷, 修明慧, 杜籼芹, 和建政, 蔺兴遥. 基于多种化疗肠损伤发生机制的中医药防治进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 583-593.
[4]	吴蓉蓉, 陈智强, 贾翼菲, 陈宏绮, 王盼盼, 燕茹. 靶向抑制肠道菌β-葡萄糖醛酸苷酶在肿瘤预防和治疗中的应用[J]. 中国临床药理学与治疗学, 2021, 26(8): 964-974.
[5]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[6]	赵全凤, 符佩姝, 谷文睿, 郑丹, 吕宗杰, 杨洋. GnRHa用于化疗后生育力保护的循证医学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1449-1454.
[7]	田亚丽, 奉林, 赵万, 谷敏, 沈涵菁, 柴晓艳. BRCA1基因多态性与转移性食管鳞癌顺铂联合卡培他滨化疗敏感性及预后关系[J]. 中国临床药理学与治疗学, 2021, 26(10): 1118-1126.
[8]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[9]	赵文超, 邱艳芳, 谭嵘. 肿瘤治疗中靶向DNA损伤反应[J]. 中国临床药理学与治疗学, 2020, 25(8): 943-952.
[10]	唐慕菲, 沈芸竹, 张保国. CYP2D6基因多态性对托烷司琼预防化疗所致恶心呕吐效果的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 817-822.
[11]	赵妙惠，周佳妮，漆勇. 桑黄多糖调控PI3K/AKT/mTOR通路抑制肝癌腹水荷瘤小鼠及对化疗的减毒增效作用[J]. 中国临床药理学与治疗学, 2020, 25(4): 401-407.
[12]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.
[13]	徐伟平，周维英. 膀胱癌化疗药物增敏机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1060-1064.
[14]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.
[15]	郑中秋，谢伯剑，崔斌斌，柯抒晨，林义. miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 541-545.